Calithera Biosciences Reports Third Quarter 2021 Financial Results and Recent Highlights
Calithera Biosciences announced its third-quarter financial results and strategic advancements on November 9, 2021. The company acquired two investigational therapies, sapanisertib and mivavotinib, enhancing its precision oncology pipeline. Cash reserves stood at $84.5 million, expected to support operations into 2023. Revenue for the quarter was $6.8 million, primarily from a milestone payment. R&D expenses dropped to $11.6 million, while G&A expenses rose to $6.3 million. The discontinuation of the telaglenastat program was also noted, citing lack of clinical benefit.
- Acquisition of sapanisertib and mivavotinib strengthens precision oncology pipeline.
- Cash reserves of $84.5 million sufficient to fund operations into 2023.
- R&D expenses decreased to $11.6 million compared to $18.2 million year-over-year.
- Net loss for the quarter was $11.2 million.
- Discontinuation of the telaglenastat program due to lack of clinical benefit shown in interim analysis.
-- Company strengthened precision oncology clinical pipeline through acquisition of mTORC 1/2 inhibitor sapanisertib and SYK inhibitor mivavotinib from Takeda Pharmaceuticals --
-- Cash, cash equivalents and investments totaled
-- Conference call and webcast scheduled for 2:00 p.m. PT on November 9, 2021--
SOUTH SAN FRANCISCO, Calif., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced its financial results for the third quarter ended September 30, 2021.
“The last month has been one of significant change for Calithera, following the acquisition of two clinical-stage investigational therapies, sapanisertib and mivavotinib, and the presentation of interim data from our cystic fibrosis program for CB-280 that supports our approach to the treatment of CF via this mechanism,” said Susan Molineaux, PhD, president and chief executive officer of Calithera. “During this quarter, we also announced the disappointing news of the discontinuation of the telaglenastat program based on an interim analysis of the KEAPSAKE trial. Finally, we announced the promotion of Emil Kuriakose to chief medical officer and the strengthening of our board of directors with the addition of Calithera’s former chief medical officer, Keith Orford.
“We move into the end of 2021 with a keen focus on biomarker-defined cancer patient populations and remain committed to our pursuit of developing medicines to improve outcomes for people with diseases of high unmet need. Our near-term clinical development plans include leveraging our clinical and biomarker expertise in the KEAP1/NRF2 pathway by developing our mTORC1/2 inhibitor sapanisertib in squamous non-small cell lung cancer, and advancing the development of our SYK inhibitor mivavotinib in specific biomarker-defined populations of diffuse large B-cell lymphoma. By focusing on well-characterized genetic vulnerabilities with molecules that have already shown single-agent activity, we will be able to generate phase 2 data with targeted, efficient study designs over the next 12 to 18 months.”
Third Quarter 2021 and Recent Highlights
- Acquired clinical stage dual mTORC 1/2 inhibitor sapanisertib and SYK inhibitor mivavotinib from Takeda Pharmaceuticals. The acquisition significantly strengthens Calithera’s precision oncology pipeline with addition of two drugs that have both demonstrated single-agent activity in the clinic, with the greatest potential in biomarker-defined cancer patient populations. Calithera plans to initiate a phase 2 study to begin in the first quarter of 2022 that will strengthen the existing data on sapanisertib as an active single-agent drug in patients with squamous non-small cell lung cancer (NSCLC) harboring a NRF2 or KEAP1 mutation. In addition, Calithera will initiate a phase 2 study of mivavotinib in the first quarter of 2022 for the treatment of patients with diffuse large B-cell lymphoma (DLBCL) with and without mutations in MyD88 and CD79. Data from these studies generated over the next 12 to 18 months could position the company to initiate registrational studies for both molecules.
- Presented interim data from the Phase 1b clinical trial of CB-280 in patients with cystic fibrosis (CF) at North American Cystic Fibrosis Conference. Data showed CB-280 was well-tolerated, had linear PK, and demonstrated robust dose-related PD effects. Encouraging trends were seen in disease biomarkers, including increased fractional exhaled nitric oxide (FeNO) and decreased sweat chloride. A pooled analysis of treatment vs. placebo showed a positive trend in forced expiratory volume in one second (FEV1) compared to placebo. Dose escalation is ongoing with cohort 4 (300mg BID) and on track to complete enrollment by the end of the year, with the option for an additional dose cohort to enroll in 2022 if warranted.
- Announced discontinuation of phase 2 telaglenastat KEAPSAKE clinical trial in patients with NSCLC with genetic mutations in KEAP1/NRF2. Interim analysis from 40 patients demonstrated lack of clinical benefit among patients treated with telaglenastat. No differences in safety profile were seen between the two arms.
- Promoted Emil Kuriakose, MD, from vice president and head of clinical development to chief medical officer. Dr. Kuriakose succeeds Keith Orford, MD, PhD who has resigned from his position and joined the Calithera Board of Directors.
- Preclinical focus on synthetic lethality targets. In addition to the company’s clinical programs, Calithera continues to leverage its discovery engine to build a robust preclinical pipeline of undisclosed synthetic lethality targets with a focus on paralog genes. These will be announced as Calithera advances preclinical development.
Selected Third Quarter 2021 Financial Results
Cash, cash equivalents and investments totaled
Revenue was
Research and development expenses for the third quarter 2021 were
General and administrative expenses for the third quarter 2021 were
Net loss for the three months ended September 30, 2021, was
Conference Call Information
Calithera will host an update conference call today, Tuesday, November 9, at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time. The call may be accessed by dialing (855) 783-2599 (domestic) or (631) 485-4877 (international) and referring to conference ID 3797324. To access the live audio webcast or the subsequent archived recording, visit the Investors section of the Calithera website at www.calithera.com. The webcast will be recorded and available for replay on Calithera’s website for 30 days.
About Calithera
Calithera Biosciences is a clinical-stage, precision oncology biopharmaceutical company developing targeted therapies to redefine treatment for biomarker-specific patient populations. Driven by a commitment to rigorous science and a passion for improving the lives of people impacted by cancer and other life-threatening diseases, Calithera is advancing a robust pipeline of investigational, small molecule oncology compounds with a biomarker-driven approach that targets genetic vulnerabilities in cancer cells to deliver new therapies for patients suffering from aggressive hematologic and solid tumor cancers for which there are currently limited treatment options.
Calithera is headquartered in South San Francisco, California. For more information about Calithera, please visit www.calithera.com.
Forward Looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "anticipate," "estimate," "intend," "poised" and similar expressions (as well as other words or expressions referencing future events, conditions, or circumstances) are intended to identify forward-looking statements. These statements include those related to Calithera’s clinical trials, timing of enrollment of the CB-280 Ph1b, sapanisertib Phase 2 and mivavotinib Phase 2 clinical trials, and the overall advancement of Calithera’s product candidates in clinical trials and Calithera’s plans to continue development of its product candidates. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. The potential product candidates that Calithera develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all. In addition, clinical trials may not confirm any safety, potency or other product characteristics described or assumed in this press release. Such product candidates may not be beneficial to patients or be successfully commercialized. The failure to meet expectations with respect to any of the foregoing matters may have a negative effect on Calithera's stock price. Additional information concerning these and other risk factors affecting Calithera's business can be found in Calithera's periodic filings with the Securities and Exchange Commission at www.sec.gov. These forward-looking statements are not guarantees of future performance and speak only as of the date hereof, and, except as required by law, Calithera disclaims any obligation to update these forward-looking statements to reflect future events or circumstances.
| Calithera Biosciences, Inc. | ||||||||||||||||
| Selected Consolidated Statements of Operations Financial Data | ||||||||||||||||
| (in thousands, except per share amounts) | ||||||||||||||||
| (unaudited) | ||||||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
| 2021 | 2020 | 2021 | 2020 | |||||||||||||
| Revenue: | ||||||||||||||||
| License revenue | $ | 6,750 | $ | — | $ | 9,750 | $ | — | ||||||||
| Total revenue | 6,750 | — | 9,750 | — | ||||||||||||
| Operating expenses: | ||||||||||||||||
| Research and development | 11,556 | 18,157 | 39,715 | 53,938 | ||||||||||||
| General and administrative | 6,344 | 4,744 | 16,259 | 14,786 | ||||||||||||
| Total operating expenses | 17,900 | 22,901 | 55,974 | 68,724 | ||||||||||||
| Loss from operations | (11,150 | ) | (22,901 | ) | (46,224 | ) | (68,724 | ) | ||||||||
| Interest and other income (expense), net | (22 | ) | 167 | 346 | 1,153 | |||||||||||
| Net loss | $ | (11,172 | ) | $ | (22,734 | ) | $ | (45,878 | ) | $ | (67,571 | ) | ||||
| Net loss per share, basic and diluted | $ | (0.15 | ) | $ | (0.32 | ) | $ | (0.62 | ) | $ | (0.99 | ) | ||||
| Weighted average common shares used to compute net loss per share, basic and diluted | 74,114 | 70,559 | 73,480 | 68,219 | ||||||||||||
| Calithera Biosciences, Inc. | ||||||||
| Selected Consolidated Balance Sheet Financial Data | ||||||||
| (in thousands) | ||||||||
| (unaudited) | ||||||||
| September 30, | December 31, | |||||||
| 2021 | 2020 | |||||||
| Balance Sheet Data: | ||||||||
| Cash, cash equivalents and investments | $ | 84,493 | $ | 115,151 | ||||
| Working capital | 72,804 | 100,302 | ||||||
| Total assets | 89,971 | 125,587 | ||||||
| Total liabilities | 15,552 | 23,216 | ||||||
| Accumulated deficit | (422,116 | ) | (376,238 | ) | ||||
| Total stockholders’ equity | 74,419 | 102,371 | ||||||
CONTACTS:
Stephanie Wong
ir@Calithera.com
650.870.1063
INVESTORS:
Burns McClellan
Lee Roth
212.213.0006
lroth@burnsmc.com
MEDIA:
Sam Brown, Inc.
Hannah Hurdle
805.338.4752
hannahhurdle@sambrown.com
FAQ
What are Calithera's financial results for Q3 2021?
What is the cash position of Calithera as of September 30, 2021?
What therapies did Calithera acquire from Takeda Pharmaceuticals?
What clinical trials are planned for sapanisertib and mivavotinib?
What was the outcome of the telaglenastat clinical trial?
